D-0672-2017 Class III Terminated
FDA drug recall D-0672-2017 was initiated by Valeant Pharmaceuticals North America LLC on Mar 20, 2017 and is designated Class III. Reason for recall: Discoloration. The recall status is terminated (terminated Jun 14, 2019). Affected quantity: 38,767 units.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 26, 2017
- Initiation Date
- Mar 20, 2017
- Termination Date
- Jun 14, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 38,767 units
Product description
CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04
Reason for recall
Discoloration.
Distribution pattern
nationwide
Code information
Lot #: 15J1277, Exp. 04/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0672-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026